Etanercept SFP in RA Patients

Phase 3 Completed 224 enrolled Amgen Wyeth is now a wholly owned subsidiary of Pfizer · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Purpose of this study is to evaluate the immunogenicity and overall safety of etanercept SFP therapy administered once weekly for 24 weeks to subjects with rheumatoid arthritis.

Timeline

Start: 2006-12
Primary completion: 2007-08
Completion: 2007-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etanercept	Protein / enzyme biologic	50 mg	—

Etanercept SFP in RA Patients

Summary

Timeline

Drugs

Indications